Pfizer Patent-Cliff Exposure & CMS Drug Spending Portfolio
Pfizer (New York, NY): 214 reconciled FDA prescription therapies (16.0% 2025 to 2030 cliff risk), $12.57B 2024 CMS Part D & Medicaid spend, and 555 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Headquarters / Cluster | New York, NY |
| Reconciled FDA Portfolio Therapies | 214 |
| 2025 to 2030 Patent-Cliff Revenue Exposure | 16.0% |
| Primary Portfolio LOE Date | 2026-01-01 |
| 2024 CMS Total Public Spend | $12.57B |
| 2024 Medicare Part D Spend | $9.43B |
| 2024 Medicaid Spend | $3.14B |
| California HCAI SB 17 Filings | 555 WAC filings (max 806.2% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Pfizer across sibling Meru public-data platforms.